A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition

Buchbinder, EI; Giobbie-Hurder, A; Ott, PA

Buchbinder, EI (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.;Buchbinder, EI (通讯作者)，Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.;Buchbinder, EI (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (3): 365

Abstract

Background: Prognosis for patients with metastatic melanoma has been improved dramatically with the development of BRAF/MEK directed therapy and immun......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索